MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.07
-0.37
-3.92%
After Hours: 9.07 0 0.00% 16:03 03/03 EST
OPEN
9.60
PREV CLOSE
9.44
HIGH
9.80
LOW
8.93
VOLUME
13.14M
TURNOVER
--
52 WEEK HIGH
19.39
52 WEEK LOW
1.550
MARKET CAP
2.54B
P/E (TTM)
-6.8895
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 8h ago
Sorrento Therapeutics' Investigational Nasal Drop Treatment For COVID-19 Cleared For Phase 1 Trial
MT Newswires · 15h ago
DJ Sorrento Therapeutics Shares Rise Following FDA Clearing Path for Covid-19 Nasal Drops Trial
Dow Jones · 23h ago
BRIEF-Sorrento Receives U.S. FDA Clearance To Proceed With Phase 1 Study For STI-2099 (Intranasal COVIDROPS)
reuters.com · 23h ago
Sorrento wins FDA go-ahead for early-stage STI-2099 COVID-19 trial
Sorrento Therapeutics (SRNE) has received clearance from the FDA for its Investigational New Drug application ((IND)) for its Phase 1 study of the safety and pharmacokinetics of intranasal ((IN)) STI-2099 ((COVIDROPS))
Seekingalpha · 23h ago
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of STI-2020 (...
GlobeNewswire · 1d ago
Sorrento gets FDA go ahead for STI-6643 trial in solid tumor
The FDA has cleared Sorrento Therapeutics (SRNE) to initiate clinical trail of internally developed anti-CD47 monoclonal antibody, STI-6643.The initial clinical trial will be a basket trial entitled “A Phase 1B, Open-Label, Dose-Escalation
Seekingalpha · 1d ago
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be conducted at the Moffitt Cancer Center in Tampa, FL with Dr. ...
GlobeNewswire · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRNE stock price target is 28.00 with a high estimate of 35.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 313
Institutional Holdings: 84.37M
% Owned: 30.10%
Shares Outstanding: 280.32M
TypeInstitutionsShares
Increased
80
10.46M
New
89
999.86K
Decreased
38
4.35M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.85%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Chief Financial Officer
Najjam Asghar
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
Edgar Lee
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
  • Dividends
  • Splits
  • Insider Activity
No Data
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.